



Protein Degradation-Based Drug Discovery (PDBDD) Approach: Proteolysis Targeting Chimeras (PROTACs)

Guest Editor:

Prof. Dr. Jia Zhou

Chemical Biology Program,
Department of Pharmacology
and Toxicology, University of
Texas Medical Branch, Galveston,
TX 77555, USA

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

Dear Colleagues,

Protein degradation-based drug discovery (PDBDD) via proteolysis targeting chimeras (PROTACs) represents a paradigm-shifting approach in small molecule drug discovery and development toward novel medications for some severe human diseases, particularly anticancer agents. Despite the fact that development of protein degraders is still at an early stage, PROTACs and related molecules capable of selectively inducing targeted protein degradation by the ubiquitin–proteasome system offer one of the most appealing therapeutic strategies with potential advantages over traditional occupancy-based inhibitors in various aspects, such as superior target specificity, better efficacy at lower dose, fewer side effects, overcoming drug resistance and modulating “undruggable” drug targets.

I would like to thank all the authors for their tremendous effort, dedication, and excellent contribution to this Special Issue. I hope that this issue will serve as a key reference work for medicinal chemists, chemical biologists, pharmacologists, and other research investigators engaged or interested in protein degradation and target-based drug discovery and development.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Chemistry, Multidisciplinary*) / CiteScore - Q1 (*Chemistry (miscellaneous)*)

Contact Us

Molecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](https://twitter.com/X@Molecules_MDPI)